Cargando…

Predictors of progression in systemic sclerosis patients with interstitial lung disease

Systemic sclerosis (SSc) is a systemic autoimmune disease affecting multiple organ systems, including the lungs. Interstitial lung disease (ILD) is the leading cause of death in SSc. There are no valid biomarkers to predict the occurrence of SSc-ILD, although auto-antibodies against anti-topoisomera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Distler, Oliver, Assassi, Shervin, Cottin, Vincent, Cutolo, Maurizio, Danoff, Sonye K., Denton, Christopher P., Distler, Jörg H.W., Hoffmann-Vold, Anna-Maria, Johnson, Sindhu R., Müller Ladner, Ulf, Smith, Vanessa, Volkmann, Elizabeth R., Maher, Toby M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236865/ https://www.ncbi.nlm.nih.gov/pubmed/32079645 http://dx.doi.org/10.1183/13993003.02026-2019

Ejemplares similares

Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression
por: Khanna, Dinesh, et al.
Publicado: (2023)

Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects
por: Maher, Toby M., et al.
Publicado: (2022)

Effect of Nintedanib on Progression of Systemic Sclerosis‐Associated Interstitial Lung Disease Over 100 Weeks: Data From a Randomized Controlled Trial
por: Assassi, Shervin, et al.
Publicado: (2022)

Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial
por: Seibold, James R, et al.
Publicado: (2020)

Is there a role for nailfold videocapillaroscopy in interstitial lung disease?
por: Smith, Vanessa, et al.
Publicado: (2022)

Understanding diagnostic pathways in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: A retrospective cohort study
por: Assassi, Shervin, et al.
Publicado: (2022)

The scientific basis for novel treatments of systemic sclerosis
por: Beyer, Christian, et al.
Publicado: (2009)

Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis
por: Beyer, Christian, et al.
Publicado: (2009)

Nintedanib in Patients With Systemic Sclerosis–Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score
por: Kuwana, Masataka, et al.
Publicado: (2022)

A broad look into the future of systemic sclerosis
por: Riemekasten, Gabriela, et al.
Publicado: (2022)

Enrichment Strategy for Systemic Sclerosis Clinical Trials Targeting Skin Fibrosis: A Prospective, Multiethnic Cohort Study
por: Mihai, Carina, et al.
Publicado: (2020)

Vascular alterations upon activation of TGFβ signaling in fibroblasts - implications for systemic sclerosis
por: Horn, Angelika, et al.
Publicado: (2010)

Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases
por: Wollin, Lutz, et al.
Publicado: (2019)

Dyspnoea and cough in patients with systemic sclerosis–associated interstitial lung disease in the SENSCIS trial
por: Volkmann, Elizabeth R, et al.
Publicado: (2022)

The role of antifibrotics in the treatment of rheumatoid arthritis–associated interstitial lung disease
por: Liang, Minrui, et al.
Publicado: (2022)

Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment
por: Bruni, Cosimo, et al.
Publicado: (2022)

Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography
por: Khanna, Dinesh, et al.
Publicado: (2022)

Systemic sclerosis in the time of COVID-19
por: Hoffmann-Vold, Anna-Maria, et al.
Publicado: (2022)

Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis−Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double‐Blind, Placebo‐Controlled Trial
por: Maher, Toby M., et al.
Publicado: (2021)

Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database
por: Hoffmann-Vold, Anna-Maria, et al.
Publicado: (2021)

Peripheral blood gene expression profiling shows predictive significance for response to mycophenolate in systemic sclerosis-related interstitial lung disease
por: Assassi, Shervin, et al.
Publicado: (2022)

Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group
por: Adler, Sabine, et al.
Publicado: (2018)

Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need
por: Herrick, Ariane L., et al.
Publicado: (2022)

Nintedanib in Patients With Autoimmune Disease–Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial
por: Matteson, Eric L., et al.
Publicado: (2022)

The need for a holistic approach for SSc-ILD – achievements and ambiguity in a devastating disease
por: Hoffmann-Vold, Anna-Maria, et al.
Publicado: (2020)

IL-21R mRNA is overexpressed in systemic sclerosis and contributes to the epidermal/dermal cross-talk
por: Distler, O, et al.
Publicado: (2003)

Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features
por: Hoffmann-Vold, Anna-Maria, et al.
Publicado: (2019)

Serum metabolites as biomarkers in systemic sclerosis-associated interstitial lung disease
por: Meier, C., et al.
Publicado: (2020)

Computed tomography-based radiomics decodes prognostic and molecular differences in interstitial lung disease related to systemic sclerosis
por: Schniering, Janine, et al.
Publicado: (2022)

Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)
por: Spagnolo, Paolo, et al.
Publicado: (2021)

Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease
por: Volkmann, Elizabeth R., et al.
Publicado: (2016)

OTUD6B-AS1 Might Be a Novel Regulator of Apoptosis in Systemic Sclerosis
por: Takata, Miki, et al.
Publicado: (2019)

Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease
por: Kreuter, Michael, et al.
Publicado: (2022)

Risk factors for mortality and mortality rates in interstitial lung disease patients in the intensive care unit
por: Huapaya, Julio A., et al.
Publicado: (2018)

The Role of Type 1 Interferon in Systemic Sclerosis
por: Wu, Minghua, et al.
Publicado: (2013)

Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)
por: Maher, Toby M, et al.
Publicado: (2023)

Tie2 as a novel key factor of microangiopathy in systemic sclerosis
por: Moritz, Falk, et al.
Publicado: (2017)

COVID-19 and systemic sclerosis: Rising to the challenge of a pandemic
por: Denton, Christopher P, et al.
Publicado: (2020)

Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases
por: Brown, Kevin K., et al.
Publicado: (2022)

Cells of the synovium in rheumatoid arthritis. Synovial fibroblasts
por: Müller-Ladner, Ulf, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_07t7do4tb3jbrls5h0l0tcqui9